Literature DB >> 16128956

The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review.

Javier P Gisbert1.   

Abstract

The rate of H. pylori recurrence after eradication of the microorganism seems to be relatively low, at least in developed countries, where the mean annual reinfection rate is of approximately 3% per patient-year of follow-up, although the risk of reinfection in some developing regions is considerably higher. Several findings suggest that recrudescence rather than reinfection is likely to be responsible for most cases of recurrence: (i) the recurrences decrease with time and decline sharply after the first year, and (ii) studies using molecular fingerprinting techniques (polymerase chain reaction [PCR]) confirm that the identified microorganisms (before and after therapy) are usually genetically identical. The lower the efficacy of an antibiotic therapy, the greater the likelihood that recurrence occur, again suggesting that in these cases temporary "clearance" has been achieved rather than true eradication. The value of the (13)C-urea breath test after treatment is higher in those patients who suffer a recurrence; therefore, selection of a lower cut-off value may be helpful to maintain the diagnostic accuracy of posttreatment breath test, and thus preventing recrudescences. The observation of a pattern of histological (active) gastritis without the concomitant finding of H. pylori must raise the suspicion of a diagnostic error. Some studies suggest that recurrence is relatively infrequent, even if the patient's spouse is H. pylori-positive, suggesting that the patient's partner does not act as a reservoir for the reinfection. However, other investigators achieve contrary results, although a common exogenous source of H. pylori (for both partner's infection and patient's reinfection) cannot be ruled out. The oral cavity may be a potential source for recrudescence of gastric infection after successful therapy. When peptic ulcer reappears (sometimes with bleeding recurrence) or gastric MALT (mucosa-associated lymphoid tissue) lymphoma relapses after previous H. pylori eradication, recolonization of the gastric mucosa by the organism has almost always occurred.

Entities:  

Mesh:

Year:  2005        PMID: 16128956     DOI: 10.1111/j.1572-0241.2005.50043.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  30 in total

1.  Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.

Authors:  Antonio Rollan; Juan Pablo Arab; M Constanza Camargo; Roberto Candia; Paul Harris; Catterina Ferreccio; Charles S Rabkin; Juan Cristóbal Gana; Pablo Cortés; Rolando Herrero; Luisa Durán; Apolinaria García; Claudio Toledo; Alberto Espino; Nicole Lustig; Alberto Sarfatis; Catalina Figueroa; Javier Torres; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Eradication of helicobacter pylori to prevent gastroduodenal diseases: hitting more than one bird with the same stone.

Authors:  Yi-Chia Lee; Jyh-Ming Liou; Ming-Shiang Wu; Chun-Ying Wu; Jaw-Town Lin
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

Review 3.  H pylori recurrence after successful eradication.

Authors:  Yaron Niv
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

Review 4.  Vaccinating against Helicobacter pylori in the developing world.

Authors:  Shamila Zawahir; Steven J Czinn; John G Nedrud; Thomas G Blanchard
Journal:  Gut Microbes       Date:  2013-11-06

Review 5.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

6.  Oral immunization with recombinant Lactobacillus acidophilus expressing the adhesin Hp0410 of Helicobacter pylori induces mucosal and systemic immune responses.

Authors:  Fan Hongying; Wu Xianbo; Yu Fang; Bai Yang; Long Beiguo
Journal:  Clin Vaccine Immunol       Date:  2013-11-27

Review 7.  Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication.

Authors:  Qing Guo; Shanqi Guo; Yizhuo Zhang
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

8.  Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.

Authors:  Douglas R Morgan; Javier Torres; Rachael Sexton; Rolando Herrero; Eduardo Salazar-Martínez; E Robert Greenberg; Luis Eduardo Bravo; Ricardo L Dominguez; Catterina Ferreccio; Eduardo C Lazcano-Ponce; Maria Mercedes Meza-Montenegro; Edgar M Peña; Rodolfo Peña; Pelayo Correa; María Elena Martínez; William D Chey; Manuel Valdivieso; Garnet L Anderson; Gary E Goodman; John J Crowley; Laurence H Baker
Journal:  JAMA       Date:  2013-02-13       Impact factor: 56.272

9.  Reinfection rate and endoscopic changes after successful eradication of Helicobacter pylori.

Authors:  Kum Hei Ryu; Sun Young Yi; Youn Ju Na; Su Jung Baik; Su Jin Yoon; Hae-Sun Jung; Hyun Joo Song
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

10.  Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile.

Authors:  Arnoldo Riquelme; Alejandro Soza; Cesar Pedreros; Andrea Bustamante; Felipe Valenzuela; Francisco Otarola; Eduardo Abbott; Marco Arellano; Brenda Medina; Alejandro Pattillo; Douglas Greig; Marco Arrese; Antonio Rollan
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.